Hematologic Oncology | Specialty

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Use of APR-246 and Oral HMAs in AML

March 8th 2021

Role of Transplant in AML

March 8th 2021

R/R Follicular Lymphoma: Third-Line Treatment Options

March 8th 2021

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

Transplantation for R/R Follicular Lymphoma

March 8th 2021

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

FDA Approves Axi-Cel for Relapsed/Refractory Indolent Follicular Lymphoma

March 6th 2021

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory indolent follicular lymphoma after 2 or more lines of systemic therapy.

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

CAR T for R/R DLBCL: Safety/Tolerability

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

March 5th 2021

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

March 4th 2021

Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Blinatumomab Significantly Prolongs EFS in Pediatric Relapsed B-ALL

March 3rd 2021

Treatment with 1 cycle of blinatumomab prior to transplant was found to result in a significant improvement in event-free survival vs standard intensive multidrug chemotherapy in pediatric patients with high-risk, first-relapse B-cell acute lymphoblastic leukemia.

Brown Breaks Down How to Choose the Optimal Frontline Approach for CLL

March 3rd 2021

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Bispecific Antibodies Could Be the Next Big Advance in Oncology

March 3rd 2021

Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.

Therapeutic Considerations in Polycythemia Vera

March 3rd 2021

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Diagnosis and Evaluation in Polycythemia Vera

March 3rd 2021

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.